Deal supported by Xplico

By |December, 2015|

Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.

Deal supported by Xplico

By |November, 2015|

LEO Pharma to acquire global dermatology portfolio from Astellas.

Deal supported by Xplico

By |November, 2015|

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis.

Deal supported by Xplico

By |November, 2015|

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes.

Deal supported by Xplico

By |October, 2015|

Nuevolution Announces Drug Discovery Collaboration with Johnson & Johnson Innovation.

Deal supported by Xplico

By |August, 2015|

PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for
APLIDIN® (plitidepsin) in oncology.

Deal supported by Xplico

By |August, 2015|

Inovio Pharmaceuticals enters into Strategic Cancer Vaccine Collaboration and License Agreement with MedImmune

Deal supported by Xplico

By |July, 2015|

PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers

Deal supported by Xplico

By |June, 2015|

LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions

Deal supported by Xplico

By |May, 2015|

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

Deal supported by Xplico

By |April, 2015|

HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction

Deal supported by Xplico

By |April, 2015|

4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan

Deal supported by Xplico

By |April, 2015|

Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

Deal supported by Xplico

By |April, 2015|

Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies

Deal supported by Xplico

By |April, 2015|

Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases

Deal supported by Xplico

By |March, 2015|

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy

Deal supported by Xplico

By |January, 2015|

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets